Injectable Contraceptives Market size was valued at USD 366.17 Mn in 2024 and is expected to reach USD 497.29 Mn by 2032, at a CAGR of 3.9%.

The Global Injectable Contraceptives Market is estimated to surpass USD 497.29 million by 2032, led by accessibility, innovation, and reproductive autonomy.”
— Navneet Kaur

WILMINGTON, DE, UNITED STATES, November 5, 2025 /EINPresswire.com/ -- The Injectable Contraceptives Market was valued at USD 366.17 million in 2024 and is expected to reach USD 497.29 million by 2032, growing at a CAGR of 3.9% during the forecast period (2025–2032).

Injectable Contraceptives Market Overview

The Injectable Contraceptives Market is experiencing consistent growth as women increasingly seek long-acting, reversible, and discreet contraceptives. Injectable contraceptives, which consist of depot medroxyprogesterone acetate (DMPA) and norethisterone enanthate (NET-EN), provide effective pregnancy prevention for one to three months per dose. These products provide women with options to fit their contraceptive preferences for convenience and dependability without requiring daily consumption.

The growth of the Injectable Contraceptives Market is being driven by increased family planning awareness, government programs to encourage contraceptive uptake, and an increase in access in both developed and developing economies. Global initiatives, including those sponsored by UNFPA, WHO, and USAID, have brought greater availability of injectable contraceptives to low- and middle-income countries while removing barriers to this method of contraception.

Additionally, technological advances, including the development of a self-administered subcutaneous injectable (DMPA-SC), will further revolutionize access to family planning. These technologies improve autonomy, privacy, and adherence among women.

Injectable Contraceptives Market Trends

Increases in Self-Injectable and Long-Lasting Formulations: Pharma companies are creating easy-to-use patient-administered subcutaneous formulations that enhance privacy, adherence, and use in both rural and urban settings.
Government and NGO Family Planning Programs: Global programs focused on women’s reproductive rights and access to healthcare, such as UNFPA and PATH, are implementing significant increases in contraceptive knowledge and uptake.
Technology Applications in MRO & Healthcare Platforms: Digital health applications for tracking, reminders, and virtual counselling, etc., are improving adherence and education.
Move Toward Hormone-Free and Biodegradable Options: Research is moving forward in the area of hormone-free biodegradable injectables that decrease side effects and improve sustainability.

Injectable Contraceptives Market Dynamics

Increased Awareness of Family Planning and Health Programs: Increased awareness regarding issues of reproductive choice and the role of family planning has led to increased uptake of modern methods of contraception. Health campaigns and educational programs continue to promote injectables as a safe, effective, and reversible method of contraception.
Increased Demand for Methods Which are Convenient and Long-Lasting: Injectables provide women with control and convenience, relieving women from the need to remember taking a daily pill. The brand Depo-Provera, for example, has been a significant driver of demand because of its three-month duration and efficacy of 96%.
Barriers of Access and Misconceptions: Disruptions in the supply chain continue to be a barrier to uptake, as do misconceptions about side effects, which continue to affect uptake in several developing nations. Public education campaigns have helped address these barriers.
Government and NGO Partnerships Provide Essential Support for Distribution: Collaborative projects such as UNFPA’s 2023 partnership with the Ministry of Health in Kenya successfully provided millions of women in rural and hard-to-reach areas with DMPA-SC injectables and widened health facility access, and supported gender equality objectives.
Cost and Regulatory Barriers: Strict manufacturing regulations, distribution barriers, and costs in developing markets create challenges for large-scale rollout, particularly for regions without sufficient health system infrastructure.

Injectable Segment Insights

By Type: In terms of type, the progesterone-only injectables segment leads the worldwide market, owing to their demonstrated effectiveness, safety profile, and simplicity of use. Products, including Depot Medroxyprogesterone Acetate (DMPA) and Norethisterone Enanthate (NET-EN), are widely accepted in both developed and emerging settings, with a well-established track record of long-acting duration, low failure rates, and the option for women who could not take estrogen (WHO; 2015). Combined injectable contraceptives will continue to grow at a steady rate as more women learn about their potential benefits over time.

By Age Group: The 25–34 years cohort will continue to dominate the injectable contraceptives segment, representing women during their most fertile stages, with a huge focus on family planning and spacing pregnancies. Additionally, rising employment and urbanization among women is contributing to sustained demand in the segment, coupled with government and NGO-led awareness around the safety and ease of injectable contraceptives.

Injectable Contraceptives Market Regional Insights

North America: Leads the global market due to the established healthcare system, insurance coverage, and awareness campaigns, such as Planned Parenthood. The U.S. is the country with the highest use of intramuscular and self-injectable forms in the North America region.
Asia Pacific is expected to grow at the fastest rate thanks to government-led campaigns focused on reproductive health, affordability, and local manufacturers, including Eugia Pharma, Incepta Pharmaceuticals, and PT Tunggal.
Europe: Grows steadily with increasing preferences for combined injectables and favorable policies promoting reproductive choice.
Latin America and Africa are seeing increased uptake due to partnerships between international organizations (e.g., USAID) and national governments focused on increasing access and improving supply chains.
Injectable Contraceptives Market Competitive Landscape

The Injectable Contraceptives Market is moderately consolidated, and companies are focusing on innovations, cost-effective formulations, and extending regional access. Strategic mergers, acquisitions, and partnerships are a key part of growing production capacity and increasing their presence in global markets.

Key Players:

Pfizer Inc. (U.S.)
Merck & Co., Inc. (U.S.)
Amphastar Pharmaceuticals Inc. (U.S.)
Bayer AG (Germany)
Mylan Laboratories Ltd. (U.S.)
Johnson & Johnson (U.S.)
Zhejiang Xianju Pharmaceutical Co., Ltd. (China)
Eugia Pharma (India)
Sun Pharmaceutical Industries Ltd. (India)
Incepta Pharmaceuticals (Bangladesh)
PT Tunggal (Indonesia)
Teva Pharmaceutical Industries Ltd. (Israel)

Recent Developments:

2023: The Indian Council of Medical Research (ICMR) has completed the clinical trials of the first injectable contraceptive for males in the world, and confirmed it is highly effective and safe.
2023: UNFPA and Kenya’s Ministry of Health improved access to contraceptives by introducing DMPA-SC injectables in more than 6,000 health facilities and reached 2.5 million women in Kenya.

2022: Several companies began to introduce self-administered subcutaneous injectable kits. This increased accessibility to subcutaneous DMPA and gave women greater autonomy in using this method.

FAQs

What is the growth rate of the Injectable Contraceptives Market?

Ans. The Injectable Contraceptives Market is growing at a CAGR of 3.9% during the forecast period (2025–2032).

Which region is expected to dominate the Injectable Contraceptives Market?

Ans. North America is expected to dominate the market due to high awareness, advanced healthcare infrastructure, and the strong presence of major pharmaceutical manufacturers.

What is the expected Injectable Contraceptives Market size by 2032?

Ans. The market size is expected to reach USD 497.29 million by 2032, up from USD 366.17 million in 2024.

What are the factors driving the Injectable Contraceptives Market growth?

Ans. The market growth is driven by rising awareness of family planning, government-led initiatives to improve contraceptive access, increased adoption of self-injectables, and technological advancements in formulation and delivery methods.

Stellar Market Research is launching a subscription service for the Injectable Contraceptives Market, offering detailed insights, forecasts, and expert analysis for healthcare manufacturers and policymakers.

Related Reports:

About Stellar Market Research:

Stellar Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.

Lumawant Godage
Stellar Market Research
+91 9607365656
email us here
Visit us on social media:
LinkedIn
Instagram
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklymedia.com